New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia

Inclusion criteria 1. ≥18 yrs old on the day of study consent; 2. Finasteride has been recommended for treatment of BPH by a physician; 3. PSA \<20ng/ml within the last six months; 4. Willingness to maintain any current genitourinary medications (e.g., beta agonists, alpha blockers, anticholinergics); 5. Patient is able and willing to provide written informed consent. Exclusion criteria 1. Active or past history of venous thromboembolism, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis; 2. Previous diagnosis with any prostatic malignancy or precancerous lesions (atypical glandular foci); 3. History of pelvic radiation; 4. Actively receiving intravesical therapy for bladder cancer; 5. Received treatment with any demethylating medications (azacitidine, decitabine, zebularine, guadecitabine, hydralazine); 6. Current use of warfarin; 7. Prior treatment with 5ARI medications (e.g., Finasteride or Dutasteride) in the last year; 8. Diagnosed with diabetes mellitus; 9. Diagnosed with any neurodegenerative diseases; 10. History of allergic reaction to any intravenous (IV) iron replacement products; 11. Currently taking cholestyramine medication; 12. Contraindications to MRI examination, which may include: * Cardiac pacemaker * Intracranial clips, metal implants, or external clips within 10mm of the head * Previous metal injury in the eye or occupation risk to ferrous metal in the eye (e.g. metalworker) * Claustrophobia that cannot be managed with benzodiazepine